Exactech's Equinoxe Shoulder System: 10 Years of Success - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:55PM CST
Developer of orthopedic implant devices Exactech Inc. (EXAC) recently announced the 10th year anniversary of its Equinoxe Shoulder System, a product line in its shoulder business.
ZMH: 114.11 (+0.64), GMED: 24.37 (+0.44), EXAC: 22.68 (+0.24), SYK: 96.00 (-0.61)
Industry's Fastest Growing Shoulder System Marks 10 Years of Improving Patient Outcomes
Business Wire - Mon Nov 17, 7:08AM CST
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, this week recognizes the 10th anniversary of its unique Equinoxe(R) Shoulder System.
EXAC: 22.68 (+0.24)
Exactech's (EXAC) Octane Elevate to Advance Spine Surgery - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:15PM CST
Developer of orthopedic implant devices, Exactech Inc. (EXAC), recently announced the launch of Octane Elevate, a self-distracting lumber fusion device made of Poly Ether Ether Ketone (PEEK), a colorless organic thermoplastic polymer.
ZMH: 114.11 (+0.64), GMED: 24.37 (+0.44), EXAC: 22.68 (+0.24), SYK: 96.00 (-0.61)
Globus Medical to Redefine Spinal Fusion with ALTERA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:07PM CST
Manufacturer of musculoskeletal implants, Globus Medical Inc. (GMED), recently announced the launch of ALTERA, which is claimed to be the first minimally intrusive expandable spacer.
ZMH: 114.11 (+0.64), GMED: 24.37 (+0.44), EXAC: 22.68 (+0.24), SYK: 96.00 (-0.61)
Exactech (EXAC) Down to Strong Sell On Dismal Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 12:30PM CST
Exactech Inc.'s (EXAC) lackluster third-quarter 2014 results (reported on Oct 21), with both earnings and revenues missing expectations, have set a negative earnings estimate revision trend for the company.
ICUI: 83.38 (+1.63), BABY: 36.45 (+1.14), EXAC: 22.68 (+0.24), IDXX: 148.68 (+1.45)
Exactech Offers High Growth And Trades At A Discount To Fair Value
Jonathan Weber - at Seeking Alpha - Wed Nov 12, 12:16PM CST
EXAC: 22.68 (+0.24)
Exactech Launches Octane(R) Elevate Peek Spacer System For Lumbar Interbody Fusion Procedures
Business Wire - Tue Nov 11, 6:56AM CST
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announces that its spine division has launched Octane(R) Elevate, a Poly Ether Ether Ketone (PEEK) spacer system, at the North American Spine Society Annual Meeting (NASS).
EXAC: 22.68 (+0.24)
Exactech Shares Down 10.1% Since SmarTrend's Sell Call (EXAC)
Comtex SmarTrend(R) - Thu Oct 30, 11:08AM CDT
SmarTrend identified a Downtrend for Exactech (NASDAQ:EXAC) on July 17th, 2014 at $23.77. In approximately 4 months, Exactech has returned 10.14% as of today's recent price of $21.36.
EXAC: 22.68 (+0.24)
Organ and Tissue Transplantation Markets - Global Strategic Business Report 2014-2020
M2 - Thu Oct 30, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zx4hg8/organ_and_tissue) has announced the addition of the "Organ and Tissue Transplantation - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs) The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: - Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine) - Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), - Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report profiles 24 companies including many key and niche players such as: - CryoLife, Inc - Exactech, Inc - Folio Biosciences - K?hler Chemie - LifeCell Corporation - Medtronic, Inc. - Organogenesis, Inc. - Organ Recovery Systems - Organ Transport Systems - XVIVO Perfusion AB Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. MARKET TRENDS 3. TECHNOLOGICAL INNOVATIONS 4. MAJOR ISSUES IMPACTING TRANSPLANTATION MARKET 5. PRODUCT OVERVIEW 6. ARTIFICIAL ORGANS - AN ALTERNATIVE TO SOLID ORGAN TRANSPLANTS 7. PRESERVATION SOLUTIONS & IMMUNOSUPPRESSANT DRUGS 8. REGULATORY ENVIRONMENT 9. PRODUCT DEVELOPMENT/INNOVATIONS 10. RECENT INDUSTRY ACTIVITY 11. FOCUS ON SELECT GLOBAL PLAYERS 12. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 24 - The United States (21) - Europe (2) - - Germany (1) - - Rest of Europe (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/zx...and_tissue
MDT: 74.08 (+0.31), EXAC: 22.68 (+0.24), CRY: 11.53 (+0.38)
Global Organ and Tissue Transplantation Market
PR Newswire - Thu Oct 23, 4:35PM CDT
This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments - Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs). The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine), Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), and Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 24 companies including many key and niche players such as -
EXAC: 22.68 (+0.24), CRY: 11.53 (+0.38)
Exactech's (EXAC) CEO David Petty on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 22, 2:57PM CDT
EXAC: 22.68 (+0.24)
Exactech posts 3Q profit
Automated Insights - Tue Oct 21, 3:28PM CDT
GAINSVILLE, Fla. (AP) _ Exactech Inc. (EXAC) on Tuesday reported net income of $3 million, or 21 cents per share, in its third quarter.
EXAC: 22.68 (+0.24)
Exactech Q3 Revenue Up 4% to $57.9 Million; Net Income Down 6% to $3.0 Million Due to Currency Losses; Q3 Diluted EPS $0.21 vs. $0.23
Business Wire - Tue Oct 21, 3:00PM CDT
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today revenue of $57.9 million for the third quarter of 2014, a 4% increase over $55.7 million in the third quarter of 2013. Net income was $3.0 million, or $0.21 per diluted share, compared to $3.2 million, or $0.23 per diluted share, in the same quarter a year ago.
EXAC: 22.68 (+0.24)
Shares of EXAC Down 15.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 16, 9:33AM CDT
SmarTrend identified a Downtrend for Exactech (NASDAQ:EXAC) on July 17th, 2014 at $23.77. In approximately 3 months, Exactech has returned 15.72% as of today's recent price of $20.03.
EXAC: 22.68 (+0.24)
Nasdaq stocks posting largest volume increases
AP - Wed Oct 15, 5:08PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CHFN: 11.36 (-0.07), ARTW: 4.97 (+0.02), PPHM: 1.40 (+0.01), PENX: 18.83 (+0.04), LAKE: 8.94 (+0.07), EXAC: 22.68 (+0.24), NAUH: 2.93 (+0.11), COVS: 2.73 (+0.08), UPIP: 1.05 (+0.03), JAXB: 12.26 (+0.96), CEMI: 3.98 (+0.08), DENN: 9.96 (+0.05)
Nasdaq stocks posting largest percentage decreases
AP - Wed Oct 15, 5:08PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
IMDZ: 34.96 (+0.78), CENT: 8.66 (+0.06), AXDX: 18.47 (+0.03), KTCC: 7.99 (unch), CENTA: 9.30 (+0.06), EXAC: 22.68 (+0.24), LAKE: 8.94 (+0.07), MTEX: 28.96 (unch), IKNX: 15.00 (-0.19)
Best U.S. Stock Ideas Today
Aviate - Seeking Alpha - Wed Oct 15, 8:52AM CDT
1. United Rentals: cover short and revisit post earnings 2. Citi: Discount to peers on a TBV buy case still intact 3. Intel: Microchip should have said it’s me not you 4. Europe FX headwinds persist 5. Technicals 6. Trader...
UTX: 116.91 (-0.30), C: 54.54 (+0.12), RBS: 12.31 (+0.14), CA: 31.31 (-0.02), INTC: 37.44 (+0.01), EXAC: 22.68 (+0.24), EMC: 30.69 (+0.14), URI: 104.84 (+0.16), FDX: 176.42 (-0.52), KO: 42.94 (-0.03), BUD: 115.51 (+0.09), HAR: 105.30 (+0.11), SWKS: 74.32 (+0.92), HSON: 3.01 (+0.01), DTE: 87.94 (+1.53), ITW: 97.11 (-0.10), SO: 49.91 (+0.74), PCLN: 1,149.78 (+2.17), ASML: 109.64 (+0.51), DISH: 72.63 (+0.54), BWA: 55.67 (-0.72), PH: 130.85 (-0.21), FLR: 60.30 (-0.26), ADSK: 60.99 (+0.34), JCI: 48.50 (-0.23)
Exactech Schedules Q3 2014 Earnings Release and Conference Call
Business Wire - Mon Oct 13, 3:50PM CDT
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its third quarter 2014 financial results on Tuesday, October 21st, 2014. A copy of the earnings release will be available at http://www.hawkassociates.com.
EXAC: 22.68 (+0.24)